Scientific Terms
Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines
The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers
The drug, MS21, has shown preclinically to inhibit growth of tumor cells with mutations in the PI3K/PTEN/AKT pathway.
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
Genomes of Advanced Neuroendocrine Neoplasms Unveil Subtypes, Treatment Clues
By sequencing dozens of locally advanced or metastatic neuroendocrine neoplasm samples, researchers detected somatic mutations that varied with primary tumor site and subtype.
Blueprint Medicines Q2 Revenues Increase More Than 200 Percent
In the second quarter, Blueprint reported $8.5 million in revenue from Ayvakit and $2.9 million in revenue from Gavreto.
Jul 29, 2021
AstraZeneca Q2 Revenues Increase 31 Percent
Jul 28, 2021
Strata Oncology Raises $90M in Series C Financing
Jul 27, 2021
Kiromic BioPharma Acquires InSilico Solutions
Jul 19, 2021